心肌-背景比f18 -氟脱氧葡萄糖PET对心脏结节病的诊断和治疗效果评价

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature Pub Date : 2025-07-03 DOI:10.1016/j.ijcha.2025.101737

Laura Ueberham , Theresa Kluge , Konrad Latuscynski , Hans Ebbinghaus , Joanna Jozwiak-Nozdrzykowska , Stephan Renziehausen , Annika Reuser , Kerstin Bode , Regine Kluge , Ulrich Laufs , Osama Sabri , Borislav Dinov

{"title":"心肌-背景比f18 -氟脱氧葡萄糖PET对心脏结节病的诊断和治疗效果评价","authors":"Laura Ueberham , Theresa Kluge , Konrad Latuscynski , Hans Ebbinghaus , Joanna Jozwiak-Nozdrzykowska , Stephan Renziehausen , Annika Reuser , Kerstin Bode , Regine Kluge , Ulrich Laufs , Osama Sabri , Borislav Dinov","doi":"10.1016/j.ijcha.2025.101737","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) is recommended for diagnosis and evaluation of therapy in patients with cardiac sarcoidosis (CS).</div></div><div><h3>Objectives</h3><div>FDG uptake parameters were investigated semi-quantitatively in biopsy-proven CS at time of diagnosis (CSD) and during immunosuppressive therapy (CST) and in controls.</div></div><div><h3>Methods</h3><div>We studied 11 patients with endomyocardial biopsy-proven CS and 15 controls. FDG uptake was assessed as myocardial-to-background ratio (MBR) of standardized uptake values in the 17-segment model and right ventricle in relation to clinical baseline parameters and changes during follow-up (FU).</div></div><div><h3>Results</h3><div>MBRs per cardiac segment in controls were below 2.1 in all control patients. In CSD, median MBR was 2.4 (IQR 1.3; 4.0), highest septal and anterobasal. In CST, median MBR was 1.5 (IQR 1.1; 1.7) with a significant reduction of mean MBRs from baseline per cardiac segment (z −9.5, p < 0.001). Patients with clinical progress showed higher MBRs and more affected cardiac segments before therapy (n = 2, MBR 4.3 ± 3.0, 18.0 ± 0) than patients with stable disease (n = 5, MBR 2.8 ± 1.2, 14.4 ± 4.6) or clinical improvement (n = 4, MBR 2.6 ± 2.5, 8.0 ± 7.4, p = n.s.) Applying a new score based on mean MBR times number of involved segments showed highest values in patients with clinical progression.</div></div><div><h3>Conclusion</h3><div>MBRs per cardiac segment can be used as a semiquantitative tool to evaluate FDG uptake in patients with CS with a cut-off ≥2.1 for relevant pathologic uptake. The clinical course may correlate with the number of affected cardiac segments and the MBRs per segment.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101737"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response\",\"authors\":\"Laura Ueberham , Theresa Kluge , Konrad Latuscynski , Hans Ebbinghaus , Joanna Jozwiak-Nozdrzykowska , Stephan Renziehausen , Annika Reuser , Kerstin Bode , Regine Kluge , Ulrich Laufs , Osama Sabri , Borislav Dinov\",\"doi\":\"10.1016/j.ijcha.2025.101737\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div><sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) is recommended for diagnosis and evaluation of therapy in patients with cardiac sarcoidosis (CS).</div></div><div><h3>Objectives</h3><div>FDG uptake parameters were investigated semi-quantitatively in biopsy-proven CS at time of diagnosis (CSD) and during immunosuppressive therapy (CST) and in controls.</div></div><div><h3>Methods</h3><div>We studied 11 patients with endomyocardial biopsy-proven CS and 15 controls. FDG uptake was assessed as myocardial-to-background ratio (MBR) of standardized uptake values in the 17-segment model and right ventricle in relation to clinical baseline parameters and changes during follow-up (FU).</div></div><div><h3>Results</h3><div>MBRs per cardiac segment in controls were below 2.1 in all control patients. In CSD, median MBR was 2.4 (IQR 1.3; 4.0), highest septal and anterobasal. In CST, median MBR was 1.5 (IQR 1.1; 1.7) with a significant reduction of mean MBRs from baseline per cardiac segment (z −9.5, p < 0.001). Patients with clinical progress showed higher MBRs and more affected cardiac segments before therapy (n = 2, MBR 4.3 ± 3.0, 18.0 ± 0) than patients with stable disease (n = 5, MBR 2.8 ± 1.2, 14.4 ± 4.6) or clinical improvement (n = 4, MBR 2.6 ± 2.5, 8.0 ± 7.4, p = n.s.) Applying a new score based on mean MBR times number of involved segments showed highest values in patients with clinical progression.</div></div><div><h3>Conclusion</h3><div>MBRs per cardiac segment can be used as a semiquantitative tool to evaluate FDG uptake in patients with CS with a cut-off ≥2.1 for relevant pathologic uptake. The clinical course may correlate with the number of affected cardiac segments and the MBRs per segment.</div></div>\",\"PeriodicalId\":38026,\"journal\":{\"name\":\"IJC Heart and Vasculature\",\"volume\":\"59 \",\"pages\":\"Article 101737\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJC Heart and Vasculature\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S235290672500140X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJC Heart and Vasculature","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S235290672500140X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

背景：18f -氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）被推荐用于心脏结节病（CS）患者的诊断和治疗评估。目的对活检证实的CS在诊断（CSD）和免疫抑制治疗（CST）期间及对照组中fdg摄取参数进行半定量研究。方法我们研究了11例经心内膜肌活检证实的CS患者和15例对照组。FDG摄取以17节段模型和右心室的标准化摄取值的心肌与背景比（MBR）与临床基线参数和随访期间变化（FU）的关系来评估。结果对照组每心段smbr值均低于2.1。CSD中位MBR为2.4 (IQR为1.3；4.0)，最高间隔和前基底。CST中位MBR为1.5 (IQR为1.1；1.7)，每心段平均MBRs较基线显著降低(z - 9.5, p <；0.001)。与病情稳定（n = 5, MBR 2.8±1.2,14.4±4.6）或临床改善（n = 4, MBR 2.6±2.5,8.0±7.4,p = ns）的患者相比，临床进展患者治疗前MBR更高，受影响心段数更多（n = 2, MBR 4.3±3.0,18.0±0）。应用基于平均MBR乘以受累节段数的新评分，在患者的临床进展中显示出最高的值。结论每心段mbr可作为半定量评估CS患者FDG摄取的工具，相关病理摄取的临界值≥2.1。临床病程可能与受影响的心脏节段数量和每个节段的mbr有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response

查看原文本刊更多论文

Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response

Background

¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) is recommended for diagnosis and evaluation of therapy in patients with cardiac sarcoidosis (CS).

Objectives

FDG uptake parameters were investigated semi-quantitatively in biopsy-proven CS at time of diagnosis (CSD) and during immunosuppressive therapy (CST) and in controls.

Methods

We studied 11 patients with endomyocardial biopsy-proven CS and 15 controls. FDG uptake was assessed as myocardial-to-background ratio (MBR) of standardized uptake values in the 17-segment model and right ventricle in relation to clinical baseline parameters and changes during follow-up (FU).

Results

MBRs per cardiac segment in controls were below 2.1 in all control patients. In CSD, median MBR was 2.4 (IQR 1.3; 4.0), highest septal and anterobasal. In CST, median MBR was 1.5 (IQR 1.1; 1.7) with a significant reduction of mean MBRs from baseline per cardiac segment (z −9.5, p < 0.001). Patients with clinical progress showed higher MBRs and more affected cardiac segments before therapy (n = 2, MBR 4.3 ± 3.0, 18.0 ± 0) than patients with stable disease (n = 5, MBR 2.8 ± 1.2, 14.4 ± 4.6) or clinical improvement (n = 4, MBR 2.6 ± 2.5, 8.0 ± 7.4, p = n.s.) Applying a new score based on mean MBR times number of involved segments showed highest values in patients with clinical progression.

Conclusion

MBRs per cardiac segment can be used as a semiquantitative tool to evaluate FDG uptake in patients with CS with a cut-off ≥2.1 for relevant pathologic uptake. The clinical course may correlate with the number of affected cardiac segments and the MBRs per segment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

IJC Heart and Vasculature Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.90

自引率

10.30%

发文量

216

审稿时长

56 days

期刊介绍： IJC Heart & Vasculature is an online-only, open-access journal dedicated to publishing original articles and reviews (also Editorials and Letters to the Editor) which report on structural and functional cardiovascular pathology, with an emphasis on imaging and disease pathophysiology. Articles must be authentic, educational, clinically relevant, and original in their content and scientific approach. IJC Heart & Vasculature requires the highest standards of scientific integrity in order to promote reliable, reproducible and verifiable research findings. All authors are advised to consult the Principles of Ethical Publishing in the International Journal of Cardiology before submitting a manuscript. Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression.